Pembrolizumab for the treatment of non-small-cell lung cancer
- PMID: 25891174
- DOI: 10.1056/NEJMoa1501824
Pembrolizumab for the treatment of non-small-cell lung cancer
Abstract
Background: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit.
Methods: We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients). We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score). Response was assessed every 9 weeks by central review.
Results: Common side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule. Among all the patients, the objective response rate was 19.4%, and the median duration of response was 12.5 months. The median duration of progression-free survival was 3.7 months, and the median duration of overall survival was 12.0 months. PD-L1 expression in at least 50% of tumor cells was selected as the cutoff from the training group. Among patients with a proportion score of at least 50% in the validation group, the response rate was 45.2%. Among all the patients with a proportion score of at least 50%, median progression-free survival was 6.3 months; median overall survival was not reached.
Conclusions: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).
Comment in
-
Immunotherapy: pembrolizumab-is the writing on the wall for cancer?Nat Rev Clin Oncol. 2015 Jul;12(7):371. doi: 10.1038/nrclinonc.2015.85. Epub 2015 May 12. Nat Rev Clin Oncol. 2015. PMID: 25963092 No abstract available.
Similar articles
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19. Lancet. 2016. PMID: 26712084 Clinical Trial.
-
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008. Ann Oncol. 2017. PMID: 28168303 Free PMC article. Clinical Trial.
-
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718847 Clinical Trial.
-
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.Lancet Respir Med. 2019 Apr;7(4):347-357. doi: 10.1016/S2213-2600(18)30500-9. Epub 2019 Mar 12. Lancet Respir Med. 2019. PMID: 30876831 Clinical Trial.
-
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8. Lung Cancer. 2019. PMID: 31446994
Cited by
-
Harnessing Variability Signatures and Biological Noise May Enhance Immunotherapies' Efficacy and Act as Novel Biomarkers for Diagnosing and Monitoring Immune-Associated Disorders.Immunotargets Ther. 2024 Oct 14;13:525-539. doi: 10.2147/ITT.S477841. eCollection 2024. Immunotargets Ther. 2024. PMID: 39431244 Free PMC article.
-
IL-1 receptor-associated kinase 3 (IRAK3) in lung adenocarcinoma predicts prognosis and immunotherapy resistance: involvement of multiple inflammation-related pathways.Transl Lung Cancer Res. 2024 Sep 30;13(9):2139-2161. doi: 10.21037/tlcr-24-391. Epub 2024 Sep 12. Transl Lung Cancer Res. 2024. PMID: 39430338 Free PMC article.
-
Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion.Transl Lung Cancer Res. 2024 Sep 30;13(9):2106-2115. doi: 10.21037/tlcr-24-347. Epub 2024 Sep 6. Transl Lung Cancer Res. 2024. PMID: 39430336 Free PMC article.
-
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications.Exp Hematol Oncol. 2024 Oct 19;13(1):102. doi: 10.1186/s40164-024-00570-y. Exp Hematol Oncol. 2024. PMID: 39427211 Free PMC article. Review.
-
In vivo self-assembled albumin nanoparticle elicit antitumor immunity of PD-1 inhibitor by imaging and clearing tumor-associated macrophages.Front Chem. 2024 Oct 3;12:1469568. doi: 10.3389/fchem.2024.1469568. eCollection 2024. Front Chem. 2024. PMID: 39421608 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials